FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFRtyrosine kinase inhibitors(TKIs),butthe magnitude of tumour regression is variable and transient(1,2). This heterogeneity in treatment response could result from geneti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bivona, Trever G., Hieronymus, Haley, Parker, Joel, Chang, Kenneth, Taron, Miquel, Rosell, Rafael, Moonsamy, Philicia, Dahlman, Kimberly, Miller, Vincent A., Costa, Carlota, Hannon, Gregory, Sawyers, Charles L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3541675/
https://ncbi.nlm.nih.gov/pubmed/21430781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09870
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak